Shell Asset Management’s Vir Biotechnology VIR Stock Holding History

Shell Asset Management’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$16K	Sell	2,830 -2,018	-42%	-$10.3K	﹤0.01%	1069
2025 Q2	$24K	Hold	4,848	–	–	﹤0.01%	1218
2025 Q1	$31K	Sell	4,848 -197	-4%	-$1.75K	﹤0.01%	1206
2024 Q4	$37K	Hold	5,045	–	–	﹤0.01%	1207
2024 Q3	$38K	Buy	+5,045	New	+$43.8K	﹤0.01%	1201
2024 Q1	$44K	Sell	4,896 -659	-12%	-$6.71K	﹤0.01%	1177
2023 Q4	$56K	Sell	5,555 -1,676	-23%	-$15.3K	﹤0.01%	1158
2023 Q3	$68K	Sell	7,231 -113	-2%	-$1.61K	﹤0.01%	1153
2023 Q2	$180K	Sell	7,344 -42	-0.6%	-$1.05K	0.01%	954
2023 Q1	$172K	Sell	7,386 -26	-0.4%	-$665	0.01%	980
2022 Q4	$188K	Sell	7,412 -1,505	-17%	-$36.9K	0.01%	978
2022 Q3	$172K	Sell	8,917 -2,336	-21%	-$59.4K	0.01%	1062
2022 Q2	$287K	Buy	11,253 +8,320	+284%	+$194K	0.01%	998
2022 Q1	$75K	Sell	2,933 -429	-13%	-$12.7K	﹤0.01%	1323
2021 Q4	$141K	Buy	3,362 +26	+0.8%	+$1.02K	﹤0.01%	1279
2021 Q3	$145K	Sell	3,336 -120	-3%	-$5.2K	﹤0.01%	1257
2021 Q2	$163K	Buy	+3,456	New	+$157K	﹤0.01%	1281

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Shell Asset Management's VIR Position: Q3 2025 in Review

Shell Asset Management reduced its Vir Biotechnology (VIR) stake by 42% in Q3 2025, selling an estimated $10.3K and leaving 2,830 shares worth $16K. The position accounts for ﹤0.01% of the portfolio, ranked #1069.

Shell Asset Management first reported a position in VIR in Q2 2021 and has held it in 17 quarters since. The position peaked at $287K in Q2 2022. 213 funds tracked by Wall St. Rank hold VIR as of Q3 2025.

Shell Asset Management held 2,830 shares of Vir Biotechnology worth $16K as of Q3 2025.
Shell Asset Management sold 2,018 Vir Biotechnology shares in Q3 2025, an estimated $10.3K.
Vir Biotechnology made up ﹤0.01% of Shell Asset Management's portfolio in Q3 2025, its #1069 holding.
Shell Asset Management first reported a position in Vir Biotechnology in Q2 2021 and has held it in 17 quarters since.
Shell Asset Management's Vir Biotechnology position peaked at $287K in Q2 2022.
213 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2025.

Based on Shell Asset Management's 13F filing for Q3 2025, filed 7 Nov 2025.